An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants

International Clinical Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 191-196

  Youssef, Nagy A ^a,b,c   Marx, Christine E ^a,b,c   Bradford, Daniel W ^b,c   Zinn, Sandra ^b,c   Hertzberg, Michael A ^b,c   Kilts, Jason D ^a   Naylor, Jennifer C ^a,b,c   Butterfield, Marian I ^a,b,c   Strauss, Jennifer L ^a,b,c  

^a VA Mid Atlantic Mental Illness   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antipsychotic agents; aripiprazole; clinical trial; post traumatic stress disorder; therapeutics; Veterans

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE;

AGED; AKATHISIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; FEMALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARESTHESIA; PILOT STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RATING SCALE; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; VETERAN; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; STRESS DISORDERS, POST-TRAUMATIC; VETERANS;

EID: 84862116033     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328352ef4e     Document Type: Article

References (55)

1. Ahearn EP, Mussey M, Johnson C, Krohn A, Krahn D (2006). Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week openlabel study. Int Clin Psychopharmacol 21:29-33. (Pubitemid 43175120)
2. Amaya-Jackson L, Davidson JR, Hughes DC, Swartz M, Reynolds V, George LK, Blazer DG (1999). Functional impairment and utilization of services associated with posttraumatic stress in the community. J Trauma Stress 12:709-724. (Pubitemid 30050851)
3. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington DC: American Psychiatric Association.
4. Amiel JM, Mangurian CV, Ganguli R, Newcomer JW (2008). Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry 21:613-618.
5. Anderson IM (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36. (Pubitemid 30173208)
6. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676. (Pubitemid 19154942)
7. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS (2005). Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 57:474-479. (Pubitemid 40311981)
8. Beck AT, Brown G, Berchick RJ, Stewart BL, Steer RA (1990). Relationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients. Am J Psychiatry 147:190-195. (Pubitemid 20060472)
9. Benedek D, Friedman M, Zatzick D, Ursano R (2009). Guideline Watch (March 2009): practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA: American Psychiatric Association.
10. Berger W, Mendlowicz MV, Marques-Portella C, Kinrys G, Fontenelle LF, Marmar CR, Figueira I (2009). Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 33:169-180.
11. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM (1995). The development of a Clinician-Administered PTSD Scale. J Trauma Stress 8:75-90.
12. Calhoun PS, Bosworth HB, Grambow SC, Dudley TK, Beckham JC (2002). Medical service utilization by veterans seeking help for posttraumatic stress disorder. Am J Psychiatry 159:2081-2086. (Pubitemid 35423869)
13. Connor KM, Davidson JR,Weisler RH, Ahearn E (1999). A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 14:29-31. (Pubitemid 29054590)
14. David D, Kutcher GS, Jackson EI, Mellman TA (1999). Psychotic symptoms in combat-related posttraumatic stress disorder. J Clin Psychiatry 60:29-32. (Pubitemid 29069882)
15. Davidson JR (2004). Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Int Clin Psychopharmacol 19:85-87. (Pubitemid 38316766)
16. Davidson JR, Hughes D, Blazer DG, George LK (1991). Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med 21:713-721.
17. Davidson JR, Book SW, Colket JT, Tupler LA, Roth S, David D, et al. (1997). Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 27:153-160. (Pubitemid 27042727)
18. Davidson JR, Tharwani HM, Connor KM (2002). Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebocontrolled SSRI trials. Depress Anxiety 15:75-78. (Pubitemid 34252248)
19. Davidson JR,Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, Van Meter S (2003). Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 53:188-191. (Pubitemid 36126484)
20. Dedert EA, Green KT, Calhoun PS, Yoash-Gantz R, Taber KH, Mumford MM, et al. (2009). Association of trauma exposure with psychiatric morbidity in military veterans who have served since September 11, 2001. J Psychiatr Res 43:830-836.
21. Guy W (1976). Assessment manual for psychopharmacology. Washington DC: NIMH US Dept of Health Education and Welfare.
22. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP (2003). Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 23:15-20. (Pubitemid 36164420)
23. Hamner MB, Robert S, Frueh BC (2004). Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectr 9:740-752.
24. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR (2000). Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 12:101-105. (Pubitemid 30470156)
25. Institute of Medicine (2008). Treatment of posttraumatic stress disorder: an assessment of the evidence. Washington DC: Institute of Medicine.
26. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276. (Pubitemid 18039085)
27. Kellner M (2007). Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder. Pharmacopsychiatry 40:41. (Pubitemid 46568362)
28. Kemp DE, Calabrese JR, Eudicone JM, Ganocy S, Tran QV, Mcquade RD, et al. (2010). Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies. Psychopharmacol Bull 43:5-27.
29. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52:1048-1060.
30. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
31. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, et al. (2011). Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 306:493-502.
32. Lambert MT (2006). Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans. Int Clin Psychopharmacol 21:185-187. (Pubitemid 43740311)
33. Marshall RD, Beebe KL, Oldham M, Zaninelli R (2001). Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 158:1982-1988. (Pubitemid 33104102)
34. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC (2002). Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 63:199-206. (Pubitemid 34407078)
35. Mello MF, Costa MC, Schoedl AF, Fiks JP (2008). Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr 30:358-361.
36. Meyer JM, Davis VG, Goff DC, Mcevoy JP, Nasrallah HA, Davis SM, et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273-286.
37. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B (2009). Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32:1037-1042.
38. Newcomer JW (2007). Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 (Suppl 1):20-27.
39. Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. (2009). A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry 70:487-499.
40. Nock MK, Hwang I, Sampson NA, Kessler RC (2010). Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. Mol Psychiatry 15:868-876.
41. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S (2003). Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 289:56-64. (Pubitemid 36026278)
42. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. (2006). Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 21:275-280. (Pubitemid 44162479)
43. Padala PR, List D, Petty F, Bhatia SC (2007). Adjunctive aripiprazole in combatrelated posttraumatic stress disorder. Ann Pharmacother 41:1744. (Pubitemid 47479807)
44. Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C (2008). The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 23:1-8. (Pubitemid 350294864)
45. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, et al. (2001). Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 16:331-337. (Pubitemid 33030048)
46. Poole H, Bramwell R, Murphy P (2009). The utility of the Beck Depression Inventory Fast Screen (BDI-FS) in a pain clinic population. Eur J Pain 13:865-869.
47. Reynolds GP, Kirk SL (2010). Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169-179.
48. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG (2009). An openlabel assessment of aripiprazole in the treatment of PTSD. Psychopharmacol Bull 42:69-80.
49. Thomas JL, Wilk JE, Riviere LA, Mcgurk D, Castro CA, Hoge CW (2010). Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry 67:614-623.
50. Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE, Masters BK (2003). Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull 37:135-149.
51. Villarreal G, Calais LA, Canive JM, Lundy SL, Pickard J, Toney G (2007). Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull 40:6-18.
52. Weiden PJ (2007). Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 68 (Suppl 4):34-39. (Pubitemid 46762121)
53. Wilcox HC, Storr CL, Breslau N (2009). Posttraumatic stress disorder and suicide attempts in a community sample of urban American young adults. Arch Gen Psychiatry 66:305-311.
54. Worthington JJ 3rd, Kinrys G,Wygant LE, Pollack MH (2005). Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 20:9-11. (Pubitemid 40105542)
55. Yood MU, Delorenze G, Quesenberry CP Jr., Oliveria SA, Tsai AL,Willey VJ, et al. (2009). The incidence of diabetes in atypical antipsychotic users differs according to agent-results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18:791-799.